Shares of Gilead Sciences Inc. slipped while Merck & Co. rose in the extended session Thursday after a jury awarded Merck billions in royalties over a hepatitis C drug dispute. In a patent lawsuit against Gilead, a federal jury in Delaware awarded Merck $2.54 billion in royalties over Gilead’s Sovaldi and Harvoni hepatitis C drugs, according to Reuters. Gilead shares fell 1.9% to $74.12, while Merck shares advanced 1.2% to $63.10 after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.